Ocrelizumab (Ocrevus)

Provider Order Form rev. 1/23/2025

Patient Name:	PATIENT INFORM	IATIO	N		Referral Sta	itus:	□ New R	Referral		Updated C	Order 🗆	Order Renewal		
Allergies:	Patient Name:						DOB:			Patient P	hone:			
Sex: M / F Date of Last Infusion: Next Due Date: Preferred Location: DIAGNOSIS (Please provide ICD-10 code in space provided)	Patient Address:							Pa	tient	Email:				
DIAGNOSIS (Please provide ICD-10 code in space provided) □ G35: Multiple Sclerosis Type: □ RRMS □ SPMS □ PPMS □ PRMS □ CIS □ Other: □ Description: THERAPY ADMINISTRATION & DOSING □ Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline every 6 months □ Observe patient for hypersensitivity reaction for a period of 60 minutes following each infusion. ADDITIONAL ORDERS □ CBC w/ diff □ at each dose □ every: □ Quantitative Serum Immune Globulin every 3 months □ Other: □ Quantitative Serum Immune Globulin every 3 months □ Other: □ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-	Allergies:						□ NKDA	Weigh	nt (lb:	s/kg):	Height	t (in/cm):		
□ G35: Multiple Sclerosis Type: □ RRMS □ SPMS □ PPMS □ PRMS □ CIS □ Other: □ Description: THERAPY ADMINISTRATION & DOSING □ Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline 6 months after initial dose □ Maintenance: Administer Ocrevus 600 mg IV in 500 ml 0.9% normal saline every 6 months ☑ Observe patient for hypersensitivity reaction for a period of 60 minutes following each infusion. ADDITIONAL ORDERS ■ ADDITIONAL ORDERS ■ CBC w/ diff □ at each dose □ every: □ Quantitative Serum Immune Globulin every 3 months □ Other: □ Patients on maintenance dosing who have not experienced a serious infusion reaction with any previous Ocrevus infusion may be eligible for an increased infusion rate. Reference quick notes for specifics on eligibility and dosing rate table. □ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-	Sex: □ M / □ F Date of Last Infusion: Next Due							Pre	ferre	d Location	:			
□ G35: Multiple Sclerosis Type: □ RRMS □ SPMS □ PPMS □ PRMS □ CIS □ Other: □ Description: THERAPY ADMINISTRATION & DOSING □ Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline 6 months after initial dose □ Maintenance: Administer Ocrevus 600 mg IV in 500 ml 0.9% normal saline every 6 months ☑ Observe patient for hypersensitivity reaction for a period of 60 minutes following each infusion. ADDITIONAL ORDERS ■ ADDITIONAL ORDERS ■ CBC w/ diff □ at each dose □ every: □ Quantitative Serum Immune Globulin every 3 months □ Other: □ Patients on maintenance dosing who have not experienced a serious infusion reaction with any previous Ocrevus infusion may be eligible for an increased infusion rate. Reference quick notes for specifics on eligibility and dosing rate table. □ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-	DIAGNOSIS (Pleas	e prov	ide ICD-10 co	ode in spa	ice provided)									
Other: Description: THERAPY ADMINISTRATION & DOSING Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline 6 months after initial dose Maintenance: Administer Ocrevus 600 mg IV in 500 ml 0.9% normal saline every 6 months Observe patient for hypersensitivity reaction for a period of 60 minutes following each infusion. ADDITIONAL ORDERS Wurshing Must have negative hepatitis B and TB test prior to start Hold infusion and notify provider for: Signs/symptoms of infection or planned/recent surgery. Precent live vaccines Pregnancy or neurological symptoms. Monitor vital signs with every rate change, then every 30 minutes and prior to discharge. Patients on maintenance dosing who have not experienced a serious infusion reaction with any previous Ocrevus infusion may be eligible for an increased infusion rate. Reference quick notes for specifics on eligibility and dosing rate table. Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-	-													
THERAPY ADMINISTRATION & DOSING ☐ Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline 6 months after initial dose ☐ Maintenance: Administer Ocrevus 600 mg IV in 500 ml 0.9% normal saline every 6 months ☐ Observe patient for hypersensitivity reaction for a period of 60 minutes following each infusion. ADDITIONAL ORDERS ☐ Was have negative hepatitis B and TB test prior to start ☐ Hold infusion and notify provider for: ■ Signs/symptoms of infection or planned/recent surgery. ■ recent live vaccines ■ pregnancy or neurological symptoms. ■ Monitor vital signs with every rate change, then every 30 minutes and prior to discharge. ■ Patients on maintenance dosing who have not experienced a serious infusion reaction with any previous Ocrevus infusion may be eligible for an increased infusion rate. Reference quick notes for specifics on eligibility and dosing rate table. ■ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-					SPMS		PPMS			PRMS		CIS		
Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline 6 months after initial dose	Other:		Description	:										
· · · · · · · · · · · · · · · · · · ·	□ Induction: Administer Ocrevus 300 mg IV in 250 ml 0.9% normal saline on Week 0 and Week 2 followed by 600mg IV in 500 ml 0.9% normal saline 6 months after initial dose □ Maintenance: Administer Ocrevus 600 mg IV in 500 ml 0.9% normal saline every 6 months ☑ Observe patient for hypersensitivity reaction for a period of 60 minutes following each infusion. ADDITIONAL ORDERS □ CBC w/ diff □ at each dose □ every: □ Quantitative Serum Immune Globulin every 3 months					 ☑ Tylenol 500mg ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP ☑ Benadryl ☑ Solumedrol 125mg IVP ☐ Other: ☐ Whust have negative hepatitis B and TB test prior to start ☑ Hold infusion and notify provider for: ■ Signs/symptoms of infection or planned/recent surgery. ■ recent live vaccines ■ pregnancy or neurological symptoms. ☑ Monitor vital signs with every rate change, then every 30 minutes and prior to discharge. ☑ Patients on maintenance dosing who have not experienced a serious infusion reaction with any previous Ocrevus infusion may be eligible for an increased infusion rate. Reference quick notes for specifics on eligibility and dosing rate table. ☑ Provide nursing care per Nursing Procedure, including 								
treatment failures or contraindications, MRI results, Lesion number			-											
Required Labs: Negative Hepatitis B														
Required Labs: Negative Hepatitis B	Provider Name (pr	rovider Name (print) Provider Signa						ture				Date		